Work

Interactions between hypothalamic and brainstem arousal circuits: anatomical, electrophysiological, and behavioural studies

Year: 2017
Type: dissertation
Abstract: Hypothalamic orexin and melanin-concentrating hormone (MCH) neuropeptide signalling systems act as fine-tuning mechanisms in the control of arousal and motivated behaviours. Orexin systems promote arousal through several different neural pathways in response to internal and external cues. One such pathway that was investigated in the current studies was the orexinergic/glutamatergic neurons that project to the rostroventrolateral medulla (RVLM). Neurophysiological studies revealed these neurons were activated by hypoglycaemia, which in turn, activated glutamatergic projections to adrenal sympathetic preganglionic neurons (SPN). As a consequence, this activation elevated adrenal sympathetic nerve activity (ASNA) and release of adrenaline to restore blood glucose. These findings were observed after electrical stimulation of the perifornical hypothalamus, and orexin/glutamate antagonist microinjection into the RVLM or the intermediolateral cell column of the spinal cord (IML). Other pathways examined in the current studies were the putative orexin and MCH projections to the brainstem, nucleus incertus (NI). Previous studies revealed that the NI receives an innervation from orexinergic neurons in the lateral hypothalamus (LH) and NI neurons express orexin type 1 and 2 receptors (OX1/2R) (OX2R >> OX1R). In in vitro whole-cell recordings, NI neurons were mainly depolarised via OX2R activation. In the current studies, the behavioural effects of orexin infusion into the NI were assessed, as well as the diurnal regulation of orexin inputs to NI, using quantitative immunofluorescence. Furthermore, the inputs to, and effects of MCH on, NI neurons was also investigated. Arousal in awake rats was assessed using protocols of feeding and locomotor activity. Microinfusion of orexin-A (600 pmol) into the NI of conscious, satiated rats during the light phase, increased locomotor activity recorded in automated locomotor cells (interaction between treatment and time variables: F(41, 205) = 1.863, P = 0.0026; n = 6/group) and increased cumulative food intake (interaction between treatment and time variables: F(3, 33) = 3.983, P = 0.0156; n = 12/group), compared to vehicle-treated control rats. In contrast, intra-NI infusion of MCH (600 pmol) only produced a trend towards decreased locomotor activity (interaction between treatment and time variables: F(41, 588) = 0.059, P > 1.0, n = 7-9/group) and food intake (interaction between treatment and time variables: F(3, 21) = 0.35, P = 0.79, n = 6/group), compared to vehicle-treated rats. Interestingly, in rats fasted for 6 h, prior to testing during the early dark phase, MCH (600 pmol) infusion increased food intake during the first 2 h post-infusion (P < 0.01, n = 7/group, with no significant interaction between time and treatment: F(3, 18) = 1.22; P = 0.33), with no effect on locomotor activity (interaction between treatment and time variables: F(44, 450) = 0.11, P > 1.0; n = 6/group). To better understand the expression and distribution of orexin and MCH receptors within the NI, RNAscope in situ hybridisation was used to characterise OX1R, OX2R and MCH1R mRNA distribution and colocalisation, relative to the GABA neuron marker, vesicular GABA transporter (vGAT) mRNA, in different neuron populations. A distinct and heterogenous mRNA colocalisation profile was observed. Using immunofluorescence to better understand the orexin and MCH inputs to the NI, a diurnal regulation of putative MCH axonal segments and terminations was observed, while orexin immunofluorescence appeared unchanged in the light vs dark phase. Conversely, studies of the reciprocal nature of NI and relaxin-3 projections to orexin and MCH neurons of the lateral hypothalamus revealed a minor projection directed to orexin/MCH neurons, but a stronger projection to a neighbouring calretinin-positive, GABA neuron population in the ventral part of the lateral hypothalamus. These studies have characterised novel aspects of the orexin/OX2R and MCH/MCH1R systems and their involvement in autonomic and behavioural responses related to appetite/metabolism and arousal. These findings provide direct evidence for orexin involvement in brainstem RVLM regulation of ASNA and blood glucose, and an involvement of orexin and MCH in regulating brainstem NI activity and associated arousal and feeding. Future studies will focus on functional and electrophysiological characterisation of the target neurons in lateral hypothalamus and NI in in vivo systems. The contribution of these circuits to arousal can be identified by selective activation or inhibition of target neurons in forebrain and brainstem, using optogenetic or chemogenetic techniques. The further identification of how these circuits contribute may provide a new understanding of the ascending reticular arousal system (ARAS) and sleep-wakefulness control, as well as further insights into the aetiology of disorders due to malfunction of neuromodulatory signalling systems in dementia, Parkinson’s disease, sleep disorders, and vegetative states after head trauma or coma.
Language: English
Open Access status: green
OpenAlex ID: W2915688871
Cites: 422
Cited by:
Related to: 10